The COSMIC-313 trial previously assessed the triplet of cabozantinib, nivolumab, and ipilimumab (C+N+I) vs N+I in first-line aRCC. Plasma KIM-1 was assessed at baseline and 4 weeks following the first dose. Both baseline and week 4 KIM-1 levels…
Wenxin (Vincent) Xu, MD, on KIM-1 as a prognostic marker in advanced renal cell carcinoma
